GlobeNewswire by notified

Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery


Uppsala, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of Olink High-Plex offerings as a proteomics platform of choice, with a goal of generating proteomic data at scale to augment RGC’s vast genomics information store. RGC is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics to ultimately improve patient outcomes.

The combination of RGC’s genomics capabilities with Olink’s proteomics platform aims to enable RGC to drive new advances in precision medicine by allowing for a more complete understanding of complex disease mechanisms, discovery of new biomarkers, and potential identification of new therapeutic targets. The platform strives to expand the understanding of protein pathways and disease biology, thereby improving the efficiency of target discovery and downstream drug development.

“The goal of our agreement is to optimize the Olink® Explore platform’s ability to integrate with our existing sequencing infrastructure to seamlessly enable a new layer of actionable data that lies closest to the phenotype. We have already seen early signs that layering proteomic data on top of our traditional methods using genomics is providing increased confidence in what we hypothesize,” said John Overton, Ph.D., Vice Presidentand Chief Sequencing Officer of Regeneron Genetics Center. “RGC hopes that further development and use of the Olink® Explore platform through this agreement will help to unlock a deeper understanding of the underlying biology of disease, in turn informing Regeneron’s drug discovery and development approach.”

“By combining our expertise in protein detection and measurement with RGC's expertise in genetics and vast data stores, we expect this agreement to unlock the potential of our offerings to enable proteomics at scale, thereby allowing customers like RGC to achieve extraordinary new insights into disease biology and pave the way for more effective treatment options,” said Jon Heimer, CEO of Olink. “We are proud to work with and support Regeneron Genetics Center, a leader in genetics research, to bring together the power of protein and genetic data to drive precision medicine forward.”

Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Olink forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Flagning af generalforsamlingsfuldmagter til bestyrelsen21.3.2023 15:11:18 CET | pressemeddelelse

Til Nasdaq OMX Copenhagen 21. marts 2023 Selskabsmeddelelse nr. 03/2023 Flagning af generalforsamlingsfuldmagter til bestyrelsen I henhold til bekendtgørelse nr. 1172 af 31. oktober 2017 om storaktionærer meddeles det, at der til brug for GrønlandsBANKENs generalforsamling den 28. marts 2023 har GrønlandsBANKENs bestyrelse modtaget blankostemmefuldmagter, som repræsenterer 31,38 procent af aktiekapitalens stemmerettigheder eller 564.804 stk. aktier Den 28. marts 2023, når den ordinære generalforsamling er afholdt, ophører bestyrelsens adgang til at stemme i henhold til de modtagne fuldmagter. Eventuelle henvendelser kan rettes til: GrønlandsBANKEN Martin Kviesgaard Bankdirektør Direkte telefon: +299 34 78 02 Vedhæftet fil 03.Flagning_blankofuldmagter

Announcement of the granting of Power of Attorney to the Board of Directors21.3.2023 15:11:18 CET | Press release

To Nasdaq OMX Copenhagen 21 March 2023 Company Announcement No 03/2023 Announcement of the granting of Power of Attorney to the Board of Directors Pursuant to announcement no 1172 of 31 October 2017 regarding Major Shareholders, The BANK of Greenland hereby announces, that the Board of Directors have received unqualified Powers of Attorney for use on The BANK of Greenland’s ordinary general meeting March 28, 2023, representing 31.38 percent of the company’s share capital, or 564,804 shares. 28 March 2023 upon termination of the ordinary general meeting, the right of the Board of Director’s to vote in accordance with the Powers of Attorney granted shall cease. For further information, please contact: The BANK of Greenland Martin Kviesgaard Managing Director Telephone: +299 34 78 02 E-mail: Attachment 03.Flying of flags_unqualified powers of attorney

New member proposed for election to the Board of Directors21.3.2023 14:38:36 CET | Press release

Company announcement no 6-2023 Copenhagen, March 21, 2023 New member proposed for election to the Board of Directors Konsolidator’s Board of Directors proposes that Peter Gath is elected as a new member of the Board of Directors at the company’s upcoming Annual General Meeting scheduled for 23 March 2023. Consequently, Konsolidator’s Board of Directors proposes that the company’s Board of Directors will consist of five members: the Chairman of the Board, Jesper Eigen Møller, and the members Thomas Aporta, Cecilia Hultén, Claus Jul Christiansen, and Peter Gath. Peter Gath enters the Board of Directors with over 20 years of experience as a partner from EY and KPMG. Peter is currently CFO of St. Jørgen Holding and holds multiple Board Member positions, incl. in the listed company Brødrene A & O Johansen A/S. As a Chartered Accountant with a background in audit and leadership, as well as an Adjunct Professor at Copenhagen Business School (CBS) and former Chairman of the Danish Institute of